Opioid prescribing patterns are far less skewed than initially thought. New research has found that most opioid prescriptions are actually distributed by the broad population of US general practitioners.
Opioid prescribing patterns are far less skewed than initially thought, according to a study from the Stanford School of Medicine. Previous research by the California Workers’ Compensation (CWC) Institute has suggested that the opioid overprescribing problem facing our country is mainly the cause of a small group of prolific prescribers—about 1%. However, according to the new results, most opioid prescriptions are actually distributed by the broad population of US general practitioners.
The Stanford study analyzed data from the 2013 Medicare Part D claims data set created by the Centers for Medicare and Medicaid Services. Each drug prescribed, total number of claims, and total costs were identified for each of the over 800,000 prescribers included in the study, while location and specialty was considered. The opioids of interest included prescriptions containing the commonly abused hydrocodone, oxycodone, fentanyl, morphine, methadone, hydromorphone, oxymorphone, meperidine, codeine, opium, or levorphanol.
According to the study, the top 10% of opioid prescribers accounted for 57% of opioid prescriptions in 2013—which was proportional to the top 10% of all drug prescribers accounting for 63% of all drug prescriptions. The specialties that prescribed the most opioids were family practice, internal medicine, nurse practitioner, and physician assistant. In contrast, however, the 2011 CWC study found that the top 10% of prescribers accounted for 80% of opioid prescriptions. So wherein lies the difference?
The authors mention that the answer lies in the nature of the data populations. The CWC study only investigated its compensation prescriptions from its worker population—a group with greater exposure to potential injury/pain than normal. Medicare data provided the opportunity to address the question of whether such opioid prescribing patterns occur across a national population.
“This data set indicates no special distinctions in the concentration of opioid prescribing among Medicare prescribers,” lead author Jonathan Chen, MD, PhD, said. “The earlier study suggests potentially aberrant behavior among those extreme outlier prescribers, while implying the remaining majority do not contribute much to the problem—and now we know this is not the case.”
The Stanford findings are important because they serve as a counterargument to the misconception that the brunt of efforts to crack down on opioid overprescribing should be directed at the small, specific group of pill-mill prescribers.
“[This] indicates that [these efforts] are insufficient to address the widespread overprescribing of opioids,” Dr Chen said. Instead, “efforts to curtail national opioid overprescribing must address a broad swath of prescribers to be effective.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More